Causeway Capital Management LLC purchased a new stake in shares of Smith & Nephew plc (NYSE:SNN - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 480,888 shares of the medical equipment provider's stock, valued at approximately $11,820,000. Causeway Capital Management LLC owned 0.11% of Smith & Nephew as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Principal Securities Inc. increased its stake in Smith & Nephew by 87.6% in the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after acquiring an additional 691 shares during the last quarter. R Squared Ltd purchased a new stake in Smith & Nephew during the 4th quarter valued at $41,000. National Bank of Canada FI grew its stake in shares of Smith & Nephew by 36.5% in the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock worth $41,000 after purchasing an additional 446 shares during the last quarter. Hara Capital LLC increased its stake in shares of Smith & Nephew by 391.4% during the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock valued at $60,000 after buying an additional 1,957 shares during the period. Finally, GAMMA Investing LLC raised its holdings in Smith & Nephew by 31.8% in the 4th quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider's stock worth $73,000 after purchasing an additional 718 shares in the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.
Smith & Nephew Trading Up 0.8 %
Shares of SNN stock traded up $0.21 during trading hours on Friday, reaching $25.90. 691,095 shares of the stock were exchanged, compared to its average volume of 838,713. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63. The company's 50-day moving average price is $27.43 and its 200-day moving average price is $26.50. Smith & Nephew plc has a 12-month low of $23.69 and a 12-month high of $31.72. The firm has a market capitalization of $11.32 billion, a price-to-earnings ratio of 11.99, a price-to-earnings-growth ratio of 1.26 and a beta of 0.71.
Smith & Nephew Increases Dividend
The firm also recently announced a semi-annual dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.447 per share. This represents a yield of 2.5%. This is a boost from Smith & Nephew's previous semi-annual dividend of $0.29. The ex-dividend date is Friday, March 28th. Smith & Nephew's dividend payout ratio is presently 41.20%.
Analysts Set New Price Targets
A number of research firms have recently weighed in on SNN. StockNews.com raised shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. Canaccord Genuity Group reissued a "hold" rating and set a $27.00 price target on shares of Smith & Nephew in a report on Monday, March 17th. Finally, UBS Group downgraded shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. Four analysts have rated the stock with a hold rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $27.00.
Check Out Our Latest Analysis on SNN
Smith & Nephew Profile
(
Free Report)
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
See Also
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
